Cardiovascular disease remains the leading cause of mortality globally, necessitating continuous efforts to identify novel preventative and management strategies. Amidst ongoing research into pharmacological interventions and lifestyle modifications, an unexpected avenue of protection has emerged from the realm of infectious disease prevention: the vaccine against herpes zoster, commonly known as shingles. Recent findings, unveiled at the American College of Cardiology’s Annual Scientific Session (ACC.26), suggest that individuals already contending with atherosclerotic heart disease who receive the shingles vaccine experience a profoundly reduced incidence of serious heart-related complications within a year, an effect that warrants significant attention from the medical community and public health officials alike.
This groundbreaking research focused on a particularly vulnerable demographic: adults aged 50 years and older diagnosed with atherosclerotic cardiovascular disease (ASCVD). ASCVD is a progressive condition characterized by the accumulation of plaque—a mixture of fat, cholesterol, calcium, and other substances—within the arteries. This buildup hardens and narrows the arteries, restricting blood flow to vital organs and increasing the risk of life-threatening events such as heart attacks and strokes. Given the widespread prevalence and severe consequences of ASCVD, any intervention demonstrating a significant reduction in associated risks holds immense promise for improving patient outcomes and public health.
To conduct this extensive investigation, researchers leveraged TriNetX, a vast, de-identified database encompassing electronic health records from millions of patients across the United States. This powerful tool enabled them to analyze data from over 246,822 adults meeting the study’s criteria, ensuring a robust sample size for statistical analysis. The study meticulously compared two groups: 123,411 individuals who had received at least one dose of either the Shingrix or Zostavax vaccine, and an equal number of unvaccinated individuals. Crucially, the research team employed rigorous matching techniques to ensure that both cohorts were remarkably similar in terms of demographic characteristics, pre-existing health conditions, and socioeconomic factors. This careful matching aimed to minimize confounding variables, thereby strengthening the causal inference between vaccination and observed outcomes.
The primary objective was to assess cardiovascular outcomes occurring within a specific window: from one month up to one year following vaccination for the inoculated group, or within an equivalent timeframe for their unvaccinated counterparts. The results were compelling across all measured endpoints. Vaccinated individuals demonstrated a remarkable 46% lower likelihood of experiencing a major adverse cardiac event (MACE), a composite endpoint typically including heart attack, stroke, or cardiovascular death. Furthermore, the data revealed an astounding 66% reduction in all-cause mortality among those who received the shingles vaccine. Breaking down specific cardiovascular events, the study reported a 32% decrease in the risk of myocardial infarction (heart attack), a 25% reduction in cerebrovascular accident (stroke), and a 25% lower incidence of heart failure.
Dr. Robert Nguyen, a resident physician at the University of California, Riverside, and the lead author of the study, emphasized the profound nature of these findings. He noted that the magnitude of these reductions in cardiovascular risk is substantial, underscoring the vaccine’s potential as a powerful tool in cardiovascular prevention. Dr. Nguyen highlighted that while the vaccine’s benefits in preventing shingles are well-established, its broader "cardioprotective" effects against heart attack, stroke, and death are increasingly being recognized. He further posited that these protective effects might be even more pronounced in the high-risk population of patients with existing cardiovascular disease compared to the general public, suggesting a critical role for the vaccine in secondary prevention strategies.
The mechanism by which the shingles vaccine might confer such significant cardiovascular benefits is an area of active scientific inquiry, building upon a growing understanding of the interplay between viral infections, inflammation, and cardiovascular health. Herpes zoster, commonly known as shingles, is caused by the reactivation of the varicella-zoster virus (VZV), the same virus responsible for chickenpox. After an initial chickenpox infection, VZV lies dormant in nerve cells. Years or even decades later, often triggered by stress, illness, or a weakened immune system, the virus can reactivate, traveling down nerve pathways to the skin, causing a characteristic painful rash, blisters, and often severe, long-lasting nerve pain known as postherpetic neuralgia.
Crucially, earlier epidemiological and mechanistic research has illuminated a direct link between an active shingles infection and an increased risk of acute cardiovascular events. The systemic inflammation triggered by a VZV reactivation is believed to play a central role. Viral infections can provoke a pro-inflammatory response throughout the body, leading to endothelial dysfunction—damage to the inner lining of blood vessels—and promoting a pro-thrombotic state, where blood is more prone to clotting. This heightened inflammatory and thrombotic environment can destabilize existing atherosclerotic plaques, leading to rupture and subsequent clot formation, which can block blood flow to the heart or brain, resulting in heart attacks or strokes. By preventing the shingles infection, the vaccine effectively mitigates these inflammatory and thrombotic cascades, thereby indirectly protecting the cardiovascular system from acute insults.
From a public health standpoint, these findings carry immense implications. The Centers for Disease Control and Prevention (CDC) already recommends the shingles vaccine for all healthy adults aged 50 years and older, as well as for younger individuals with compromised immune systems. This new evidence provides a compelling additional rationale for adhering to these guidelines, particularly for those with pre-existing heart conditions. The notion that a vaccine primarily designed to prevent a painful dermatological condition can also significantly reduce the burden of heart disease underscores the multifaceted benefits of vaccination as a comprehensive health intervention. In an era where medical disinformation can sow doubt about vaccine efficacy and necessity, studies like this offer robust, data-driven arguments for embracing established public health recommendations.
Dr. Nguyen underscored the broader principle: "Vaccines are one of the most important medicines we have to prevent disease." He articulated that these results offer another powerful reason for patients, particularly those with concerns or uncertainties, to choose to receive the vaccine, reinforcing its value beyond its primary indication. The potential to reduce major adverse cardiac events and all-cause mortality by such significant margins translates into an improved quality of life for countless individuals and a reduced strain on healthcare systems.
While the study presents compelling evidence, it is important to acknowledge its inherent limitations. As an observational study, it demonstrates an association rather than direct causation. Although researchers meticulously adjusted for numerous health and socioeconomic factors, it is conceivable that individuals who elect to receive vaccinations may, on average, also engage in other health-conscious behaviors not fully captured or accounted for in the analysis. This phenomenon, sometimes referred to as the "healthy vaccinee effect," could potentially influence the observed benefits. Nevertheless, the study’s substantial sample size, rigorous statistical adjustments, and the biological plausibility of the proposed mechanisms lend considerable weight to its conclusions, suggesting a meaningful reduction in cardiovascular risk attributable to shingles vaccination.
Furthermore, the current analysis tracked outcomes only within the first year following vaccination. While this provides crucial short-term data, the long-term effects warrant further investigation. However, supportive evidence comes from a previous study published in 2025, which indicated that shingles vaccination was associated with a 23% reduction in cardiovascular events in generally healthy adults, with protective effects potentially enduring for up to eight years. This earlier finding, albeit in a different patient cohort, provides a promising indication that the benefits observed in the high-risk population might also be sustained over extended periods. Future research, including longer-term follow-up studies and potentially randomized controlled trials, will be crucial to fully elucidate the enduring impact and precise mechanisms underlying this remarkable cardioprotective effect. The presentation of these findings at a major scientific conference like ACC.26 signifies their importance and the ongoing commitment of the medical community to explore all avenues for enhancing cardiovascular health.
About the Author
